{
  "type": "article",
  "title": "RML Hospital Recalls 10 Batches of Critical Medicines Over Quality and Physical Defects",
  "summary": "Dr. Ram Manohar Lohia Hospital has withdrawn 10 medicine batches used for heart conditions, epilepsy, and post-delivery care after samples failed analytical tests and showed physical degradation.",
  "content": "Dr. Ram Manohar Lohia Hospital, a central government healthcare facility, has initiated an urgent recall of 10 batches of critical medications across its clinical departments and wards. The corrective measure was triggered after hospital quality assessments revealed that several formulations failed analytical standards or suffered from severe physical degradation. Hospital inventory management authorities acted swiftly to halt the administration of these compromised supplies, directing healthcare personnel to immediately return all remaining stock to central distribution units to safeguard patient health.\n\nFour Official Recall Notices Issued Over Seven Days\nThe corrective measures unfolded through a sequence of four formal notifications circulated between September 7 and September 14. Hospital administrative circulars instructed every clinical department, outpatient desk, and inpatient ward to suspend the dispensing of the affected consignments without delay. Medical staff were asked to report any unusual patient observations, though clinical surveillance confirmed that no adverse medical episodes or critical side effects were documented among patients treated during the period.\n\nThree Oral Formulations Declared Substandard\nA notification issued on September 14 by the oral and topical drug unit confirmed that three separate tablet formulations were categorized as not of standard quality following analytical laboratory assessments. The substandard oral medications included sodium valproate 200 mg, an essential anti-epileptic therapy, alongside spironolactone 50 mg, prescribed for congestive heart failure and fluid retention. The third failed oral batch was imipramine 25 mg, an antidepressant commonly utilized in psychiatric and neurological clinical care.\n\nFive Injectable Drugs Pulled from Clinical Use\nSimultaneously on September 14, the hospital injectable drug division ordered the immediate withdrawal of five intravenous and intramuscular drug batches. Testing identified non-conformity in batches of adenosine, utilized in cardiac emergencies, and methylergometrine, a crucial medication administered to mothers to control postpartum bleeding following childbirth. The recall list for injectables also encompassed batches of pheniramine maleate, multi-vitamin injection, and ascorbic acid, prompting their comprehensive removal from hospital supply lines.\n\nPhysical Crumbling and Powder Formation in Tablet Strips\nPhysical inspections exposed severe manufacturing irregularities in two cardiac tablet lines. On September 9, a formal notice flagged that isosorbide mononitrate 20 mg tablets had degraded into loose powder inside their blister packaging. Manufactured by Glosun India Labs Private Limited in July 2026 with an expiration date of June 2028, departments were instructed to clear and return the stock within three days. A comparable defect was recorded on September 7 regarding metoprolol 50 mg tablets from Glosun India Labs, with additional supplies originating from Jackson Laboratories Private Limited.\n\nAlternative Medications and Patient Safety Safeguards\nHospital leadership stated that standard clinical protocols were activated the moment testing confirmed the non-compliant results. To ensure uninterrupted medical treatment for all admitted individuals and outpatient visitors, hospital pharmacies arranged verified alternative formulations across all affected categories. Officials emphasized that rigorous monitoring protocols remain active, ensuring patient safety while maintaining zero disruption to ongoing critical healthcare services.\n\nWhat this means for you\nThis recall directly protects patients relying on government hospital supplies from consuming degraded or ineffective medications.\n\n• For Current Patients: Alternative therapeutic substitutes have been distributed across all hospital units without interrupting ongoing treatment. Individuals recently prescribed these medications from the hospital pharmacy should verify their strips with attending physicians.\n• Safety Assurance: Tablets that crumble into powder or fail analytical benchmarks carry reduced therapeutic efficacy. Patients are strictly advised against consuming broken, degraded, or powdered pharmaceutical formulations.\n• Adverse Reaction Vigilance: Medical staff remain on high alert to observe and log any unexpected treatment responses. Patients observing any unusual symptoms should report them directly to the attending clinical team.\n• Stock Replenishment: Clinical units have a strict three-day return window to hand over all non-compliant batches. This procedural measure ensures defective inventory is completely segregated from routine patient care.\n\nWhy this happened\nThe recall was mandated after routine internal laboratory testing and physical evaluations revealed that select medicine consignments failed mandatory pharmaceutical standards.\n\n• Analytical Testing Non-Compliance: Laboratory screenings determined that three tablet formulations and five injectable drugs failed to satisfy official chemical and therapeutic specifications. Consequently, authorities formally declared these batches substandard.\n• Physical Formulation Breakdown: Blister strips containing tablets that crumbled into powder indicated major manufacturing defects or storage stability failures. Such physical defects make accurate dosage administration impossible.\n• Critical Therapeutic Needs: The affected drugs target critical conditions such as epilepsy, cardiac emergencies, and maternal postpartum bleeding. Because unverified potency poses immediate life risks, administrative protocols mandated an immediate withdrawal of all implicated batches.\n\nQuestions & Answers\n\n1. How many medicine batches were recalled by RML Hospital?\nThe hospital recalled a total of 10 batches after they failed analytical quality tests or exhibited physical defects.\n\n2. Which medical conditions were these recalled medicines intended for?\nThe withdrawn medications treat epilepsy, heart failure, depression, cardiac emergencies, and postpartum maternal bleeding.\n\n3. What physical defect was observed in the recalled tablets?\nIsosorbide mononitrate and metoprolol tablets were found degraded into loose powder inside their blister packaging.\n\n4. Were any adverse patient reactions reported from these medicines?\nHospital authorities confirmed that no severe side effects or adverse events have been reported among patients so far.\n\n5. How is the hospital ensuring that ongoing patient care is not disrupted?\nThe hospital immediately made verified alternative medications available across all departments and wards.",
  "url": "https://trendkia.com/en/health/rml-aspatala-men-gunavatta-jancha-men-phela-huin-10-davaon-ke-baicha-vapasa-mngae-gae-41859",
  "category": "Health",
  "publishedAt": "2026-10-02",
  "tags": [
    "RML Hospital",
    "Medicine Recall",
    "Drug Quality Check",
    "Health News",
    "Patient Safety",
    "Delhi Hospital"
  ],
  "language": "en",
  "site": "TrendKia"
}